
BTSG Stock Forecast & Price Target
BTSG Analyst Ratings
Bulls say
BrightSpring Health Services Inc. has demonstrated robust performance in its OP Rehab segment, with a noted growth rate in the double-digit percentage range, contributing to strong margins. The company has outlined plans to enhance its margins further and significantly boost EBITDA through strategic mergers and acquisitions, positioning itself to expand market share in the generic drug sector. Additionally, ongoing operational initiatives, along with anticipated wins in lower daily dosage (LDD) markets and pending acquisitions, are expected to bolster EBITDA estimates for 2026-2027, supporting a positive long-term outlook for the company's financial health.
Bears say
BrightSpring Health Services Inc. faces potential revenue challenges due to the risk of weakened client budgets, which may adversely impact their business operations. The company is in the process of acquiring 127 home health locations, which is anticipated to provide EBITDA benefits in 2026, though current expectations for growth appear low amid uncertainties in drug pricing and prescription practices. Furthermore, BrightSpring's significant debt load may hinder its capacity for growth investments, while the loss of a contract in 2024 further complicates their expansion opportunities in a competitive market.
This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.
BTSG Analyst Forecast & Price Prediction
Start investing in BTSG
Order type
Buy in
Order amount
Est. shares
0 shares